Nature Medicine has launched an investigation into a study published earlier this month that suggested the timing of immunotherapy treatment could significantly impact outcomes for lung cancer patients. The study, titled “Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial” and authored by Zhe Huang, Liang Zeng, Zhaohui Ruan, Qun Zeng, and others, claimed patients receiving immunotherapy experienced better results when treated in the morning versus the afternoon.
Concerns about the study’s data and methodology were first raised by scientists shortly after its publication, prompting scrutiny from the journal. Jonathan Wosen, PhD, highlighted the issues in a LinkedIn post, referencing reporting by STAT News. Anirban Maitra shared a post by Matthew Herper on X, noting the importance of critical appraisal of trial data for oncology fellows and junior faculty.
The original study focused on patients with non-small cell lung cancer undergoing treatment with nivolumab, an immunotherapy drug. Researchers analyzed genomic alterations and neoepitope immunogenicity in tumor tissue samples collected before and during treatment. A recent analysis of data from the CheckMate 153 trial, published in Nature, examined neoantigen landscapes and their relationship to nivolumab’s efficacy, identifying 196 neopeptides recognized by T cells. This research highlighted the importance of neoantigen immunogenicity in shaping treatment response.
The investigation by Nature Medicine comes amid a separate retraction of a cancer immunotherapy study over data concerns, as reported by Archyde.com. The retracted study also focused on optimizing immunotherapy treatment schedules, further underscoring the sensitivity surrounding research in this field.
As of Monday, February 23, 2026, Nature Medicine has not released a timeline for the completion of its investigation. The authors of the original study have not yet publicly commented on the concerns raised.
